viewAIM ImmunoTech Inc

Hemispherx Biopharma to begin two clinical trials at two major US cancer centers

Hemispherx BioPharma Inc (NYSE American:HEB) CEO Tom Equels sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Equels says the company will begin clinical trials at the Roswell Park Comprehensive Cancer Center to start an oncology clinical study combining its dsRNA TLR3 agonist Ampligen with Merck's Keytruda (pembrolizumab) in Metastatic Triple Negative Breast Cancer.

A second clinical trial combining Ampligen with Keytruda in ovarian cancer is scheduled to launch later this month at the University of Pittsburgh.

Quick facts: AIM ImmunoTech Inc

Price: 2.585 USD

Market: NYSE
Market Cap: $102.6 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc named herein, including the promotion by the Company of AIM ImmunoTech Inc in any Content on the Site, the Company receives...


Full interview: AIM ImmunoTech hopes to take the battle against COVID-19 to...

AIM ImmunoTech (NYSE: AIM) CEO Thomas Equels joined Proactive New York's Christine Corrado on Skype with news the immuno-pharma company announced they have joined ChinaGoAbroad to bring their experimental drug Ampligen to China. Equels telling Proactive how this drug will try to be a...

on 3/3/20

2 min read